221 related articles for article (PubMed ID: 23873941)
1. Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome.
Wang Q; Von T; Bronson R; Ruan M; Mu W; Huang A; Maira SM; Zhao JJ
Genes Dev; 2013 Jul; 27(14):1568-80. PubMed ID: 23873941
[TBL] [Abstract][Full Text] [Related]
2. The gene dosage of class Ia PI3K dictates the development of PTEN hamartoma tumor syndrome.
Wang Q; Weisberg E; Zhao JJ
Cell Cycle; 2013 Dec; 12(23):3589-93. PubMed ID: 24131925
[TBL] [Abstract][Full Text] [Related]
3. Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER
Hosford SR; Dillon LM; Bouley SJ; Rosati R; Yang W; Chen VS; Demidenko E; Morra RP; Miller TW
Clin Cancer Res; 2017 Jun; 23(11):2795-2805. PubMed ID: 27903677
[No Abstract] [Full Text] [Related]
4. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Edgar KA; Wallin JJ; Berry M; Lee LB; Prior WW; Sampath D; Friedman LS; Belvin M
Cancer Res; 2010 Feb; 70(3):1164-72. PubMed ID: 20103642
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment of cancer-prone germline PTEN mutant mice with low-dose rapamycin extends lifespan and delays tumour development.
Tibarewal P; Rathbone V; Constantinou G; Pearce W; Adil M; Varyova Z; Folkes L; Hampson A; Classen GAE; Alves A; Carvalho S; Scudamore CL; Vanhaesebroeck B
J Pathol; 2022 Dec; 258(4):382-394. PubMed ID: 36073856
[TBL] [Abstract][Full Text] [Related]
6. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
7. Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
Papakonstanti EA; Zwaenepoel O; Bilancio A; Burns E; Nock GE; Houseman B; Shokat K; Ridley AJ; Vanhaesebroeck B
J Cell Sci; 2008 Dec; 121(Pt 24):4124-33. PubMed ID: 19033389
[TBL] [Abstract][Full Text] [Related]
8. Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.
Berenjeno IM; Guillermet-Guibert J; Pearce W; Gray A; Fleming S; Vanhaesebroeck B
Biochem J; 2012 Feb; 442(1):151-9. PubMed ID: 22150431
[TBL] [Abstract][Full Text] [Related]
9. Hamartoma-like lesions in the mouse retina: an animal model of
Tachibana N; Touahri Y; Dixit R; David LA; Adnani L; Cantrup R; Aavani T; Wong RO; Logan C; Kurek KC; Schuurmans C
Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29716894
[No Abstract] [Full Text] [Related]
10. PTEN hamartoma tumor syndromes.
Blumenthal GM; Dennis PA
Eur J Hum Genet; 2008 Nov; 16(11):1289-300. PubMed ID: 18781191
[TBL] [Abstract][Full Text] [Related]
11. Class I Phosphoinositide 3-Kinase
Mazloumi Gavgani F; Smith Arnesen V; Jacobsen RG; Krakstad C; Hoivik EA; Lewis AE
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544563
[TBL] [Abstract][Full Text] [Related]
12. Imbalanced PTEN and PI3K Signaling Impairs Class Switch Recombination.
Chen Z; Getahun A; Chen X; Dollin Y; Cambier JC; Wang JH
J Immunol; 2015 Dec; 195(11):5461-5471. PubMed ID: 26500350
[TBL] [Abstract][Full Text] [Related]
13. Cerebellar phenotypes in germline PTEN mutation carriers.
Gambini D; Ferrero S; Bulfamante G; Pisani L; Corbo M; Kuhn E
Neuropathol Appl Neurobiol; 2024 Apr; 50(2):e12970. PubMed ID: 38504418
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent.
Ni J; Liu Q; Xie S; Carlson C; Von T; Vogel K; Riddle S; Benes C; Eck M; Roberts T; Gray N; Zhao J
Cancer Discov; 2012 May; 2(5):425-33. PubMed ID: 22588880
[TBL] [Abstract][Full Text] [Related]
15. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context.
Schmit F; Utermark T; Zhang S; Wang Q; Von T; Roberts TM; Zhao JJ
Proc Natl Acad Sci U S A; 2014 Apr; 111(17):6395-400. PubMed ID: 24737887
[TBL] [Abstract][Full Text] [Related]
16. Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss.
Cizmecioglu O; Ni J; Xie S; Zhao JJ; Roberts TM
Elife; 2016 Oct; 5():. PubMed ID: 27700986
[TBL] [Abstract][Full Text] [Related]
17. The phosphatidylinositol 3-kinase (PI3K) isoform dependence of tumor formation is determined by the genetic mode of PI3K pathway activation rather than by tissue type.
Utermark T; Schmit F; Lee SH; Gao X; Schaffhausen BS; Roberts TM
J Virol; 2014 Sep; 88(18):10673-9. PubMed ID: 24991009
[TBL] [Abstract][Full Text] [Related]
18. Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants.
Brewer T; Yehia L; Bazeley P; Eng C
Am J Hum Genet; 2022 Aug; 109(8):1520-1533. PubMed ID: 35931053
[TBL] [Abstract][Full Text] [Related]
19. Activity of any class IA PI3K isoform can sustain cell proliferation and survival.
Foukas LC; Berenjeno IM; Gray A; Khwaja A; Vanhaesebroeck B
Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11381-6. PubMed ID: 20534549
[TBL] [Abstract][Full Text] [Related]
20. PTEN-deficient cancers depend on PIK3CB.
Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
